Effectiveness of take-home methadone treatment among patients with opioid use disorders during COVID-19: A systematic review
Open Access
- 7 August 2024
- journal article
- review article
- Published by Elsevier in Health Sciences Review
- Vol. 12
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorderDrug and Alcohol Dependence, 2023
- Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 PandemicJAMA Psychiatry, 2022
- Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trialDrug and Alcohol Dependence, 2022
- Prioritization and sequential exclusion of articles in systematic reviewsCampbell Systematic Reviews, 2022
- Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and DiscontinuationJAMA, 2022
- Methadone exposures reported to poison control centers in the United States following the COVID-19-related loosening of federal methadone regulationsInternational Journal of Drug Policy, 2022
- Treatment provider perceptions of take-home methadone regulation before and during COVID-19Drug and Alcohol Dependence, 2021
- Syringe services program (SSP) operational changes during the COVID-19 global outbreakInternational Journal of Drug Policy, 2020
- The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisisInternational Journal of Drug Policy, 2019
- Current quality of life and its determinants among opiate-dependent individuals five years after starting methadone treatmentQuality of Life Research, 2010